Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Development and Evaluation of Two Potential 5-HT7 Receptor PET Tracers: [18F]ENL09 and [18F]ENL10

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Development and Evaluation of Two Potential 5-HT7Receptor PET Tracers: [18F]ENL09 and [18F]ENL10

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Classics in Neuroimaging: The Serotonergic 2A Receptor System-from Discovery to Modern Molecular Imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. PICK1-Deficient Mice Exhibit Impaired Response to Cocaine and Dysregulated Dopamine Homeostasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Ketogenic Diet Suppresses Alcohol Withdrawal Syndrome in Rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Physiological roles of CNS muscarinic receptors gained from knockout mice

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Michael Bubser
  • Thomas M Bridges
  • Ditte Dencker
  • Robert W Gould
  • Michael Grannan
  • Meredith J Noetzel
  • Atin Lamsal
  • Colleen M Niswender
  • J Scott Daniels
  • Michael S Poslusney
  • Bruce J Melancon
  • James C Tarr
  • Frank W Byers
  • Jürgen Wess
  • Mark E Duggan
  • John Dunlop
  • Michael W Wood
  • Nicholas J Brandon
  • Michael R Wood
  • Craig W Lindsley
  • P Jeffrey Conn
  • Carrie K Jones
Vis graf over relationer

Positive allosteric modulators (PAMs) of the M4 muscarinic acetylcholine receptor (mAChR) represent a novel approach for the treatment of psychotic symptoms associated with schizophrenia and other neuropsychiatric disorders. We recently reported that the selective M4 PAM VU0152100 produced an antipsychotic drug-like profile in rodents after amphetamine challenge. Previous studies suggest that enhanced cholinergic activity may also improve cognitive function and reverse deficits observed with reduced signaling through the N-methyl-d-aspartate subtype of the glutamate receptor (NMDAR) in the central nervous system. Prior to this study, the M1 mAChR subtype was viewed as the primary candidate for these actions relative to the other mAChR subtypes. Here we describe the discovery of a novel M4 PAM, VU0467154, with enhanced in vitro potency and improved pharmacokinetic properties relative to other M4 PAMs, enabling a more extensive characterization of M4 actions in rodent models. We used VU0467154 to test the hypothesis that selective potentiation of M4 receptor signaling could ameliorate the behavioral, cognitive, and neurochemical impairments induced by the noncompetitive NMDAR antagonist MK-801. VU0467154 produced a robust dose-dependent reversal of MK-801-induced hyperlocomotion and deficits in preclinical models of associative learning and memory functions, including the touchscreen pairwise visual discrimination task in wild-type mice, but failed to reverse these stimulant-induced deficits in M4 KO mice. VU0467154 also enhanced the acquisition of both contextual and cue-mediated fear conditioning when administered alone in wild-type mice. These novel findings suggest that M4 PAMs may provide a strategy for addressing the more complex affective and cognitive disruptions associated with schizophrenia and other neuropsychiatric disorders.

OriginalsprogEngelsk
TidsskriftA C S Chemical Neuroscience
Vol/bind5
Udgave nummer10
Sider (fra-til)920-42
Antal sider23
ISSN1948-7193
DOI
StatusUdgivet - 15 okt. 2014

ID: 44737284